Effects of Isradipine on Renal Function in Cydosporin-Treated Renal Transplanted Patients
- 1 January 1991
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 6 (10) , 725-730
- https://doi.org/10.1093/ndt/6.10.725
Abstract
The renal effects of the calcium-channel antagonist isradipine were evaluated in cyclosporin A (CsA)-treated renal allografted patients more than 5 months after transplantation. Twelve patients withstable renal function were given placebo for 2 weeks and en isradipine 1.25 mg × 2 for 1 week and 2.5 mg × 2 for the next 3 weeks in an open trial. The CsA dose wasunchanged during the study. Isradipine did not interfere with the pharmacokinetics of CsA as both whole blood trough and peak levels were unchanged. Isradipine reduced mean arterial blood pressure (MAP) from 117.0 ± 1.8 to 106.3 ± 1.9 mmHg (PPAH)increased from 256.4 ± 21.5 to 291.5 ± 26.3 ml/min (PPIn) was unchanged. Fractional proximal reabsorption, calculatedfrom lithium clearance (CLi), was reduced by 11.9% (PNa) and increased distal sodium delivery (DDNa). Distal sodium reabsorption (ADRNa) and free-water clearance (CH2O) were significantly increased. Urinary excretion of enzymes and proteins was unchanged by isradipineKeywords
This publication has 0 references indexed in Scilit: